rs8050894

A SNP in the VKORC1 gene on chromosome 16. Its most notable genotype is C;C: warfarin sensitivity (~2.5 mg/day)

Gene
VKORC1
Location
Chr 1631,093,188 (GRCh38)
Highest magnitude
2.1Worth knowing
Tested on
23andMe, AncestryDNA, FamilyTreeDNA
Minor allele frequency
49%

Genotypes

As shown in 23andMe and AncestryDNA files.

  1. C;CMost notableNot ratedwarfarin sensitivity (~2.5 mg/day)Worth knowing · 2.125% of people
  2. C;GNot ratedaverage warfarin response (~5 mg/day)Typical · 0.027% of people
  3. G;GNot ratedwarfarin resistance (~6.5 mg/day)Worth knowing · 2.148% of people

On SNPedia: (C;C), (C;G), (G;G). Magnitude rates how notable a genotype is from 0 to 10, not how risky it is.

Frequency

Share of each genotype in 4 HapMap populations.

  • AverageC;C 25% C;G 27% G;G 48%
  • European ancestry (Utah)C;C 45% C;G 37% G;G 19%
  • Han Chinese (Beijing)C;C 0% C;G 11% G;G 89%
  • Japanese (Tokyo)C;C 0% C;G 21% G;G 80%
  • Yoruba (Nigeria)C;C 54% C;G 41% G;G 5%

Conditions, medicines and genes

Other VKORC1 SNPs

All VKORC1 SNPs

Notes

From SNPedia

Show notes, about 370 words

rs8050894, is located on chromosome 16 in the gene VKORC1. VKORC1 is the primary target of the drug warfarin (Coumadin), a commonly used oral anticoagulant. rs8050894 is one of several polymorphisms found in VKORC1 that is associated with specific warfarin doses (). Other polymorphisms in VKORC1 (rs7196161, rs9923231, rs9934438, rs2359612) are equally predictive of warfarin dose requirement in both European and Asian-descent individuals. Other polymorphisms found in the gene cytochrome P450 2C9 (CYP2C9) influence the metabolism of warfarin and have a smaller effect on warfarin dose. These polymorphisms are rs1799853 (CYP2C9*2) and rs1057910 (CYP2C9*3). In several hundred Europeans, no association was found between rs8050894 and risk for ischemic stroke. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Evaluation of genetic factors for warfarin dose prediction. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction. Warfarin pharmacogenetics. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Estimation of the warfarin dose with clinical and pharmacogenetic data. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected.

Source and license

Adapted from rs8050894 on SNPedia, using a snapshot taken October 16, 2026. SNPedia content is shared under CC BY-NC-SA 3.0 US, and this page is shared under the same license.

SNPedia is a community-edited wiki. Its entries can be incomplete, out of date or wrong, and nothing here is a diagnosis or medical advice. Magnitude is a community rating of how interesting a genotype is, not a risk score.